Propranolol in hypoglycaemia unawareness.

Area of Science:

• Endocrinology
• Pharmacology
• Diabetology

Background:

• Hypoglycemia unawareness is a significant complication in insulin-dependent diabetes.
• Lack of adrenergic symptoms impairs timely hypoglycemia detection and management.
• Beta-blockers, like propranolol, can mask or alter hypoglycemic symptoms.

Purpose of the Study:

• To assess the effect of propranolol on the occurrence of hypoglycemic symptoms in patients with insulin-dependent diabetes and hypoglycemia unawareness.
• To investigate whether propranolol can restore adrenergic warning symptoms during hypoglycemia.

Main Methods:

• A 4-week, double-blind, randomized parallel group study (2:1) was conducted.
• Nine patients received propranolol (20-30 mg twice daily), and five received a matched placebo.
• Patients had a history of severe hypoglycemic episodes without adrenergic symptoms.

Main Results:

• The mean number of hypoglycemic episodes was similar between groups.
• Propranolol reduced asymptomatic hypoglycemias and increased symptomatic ones, though not statistically significant.
• Investigators reported treatment success in 5/9 propranolol patients versus 0/5 placebo patients (p = 0.038).
• Increased incidence of sweating during hypoglycemia was observed with propranolol (p = 0.06).

Conclusions:

• Propranolol may be beneficial in restoring adrenergic symptoms during hypoglycemia in diabetic patients with unawareness.
• The primary beneficial effect appears to be an increase in hypoglycemia-induced sweating.
• Larger studies are required to confirm these preliminary findings.